Biomarkers Market Size, Share & Trends Analysis Report and Segment
Forecast, 2026 | Grand View Research, Inc
“The global biomarkers market size was valued at USD 40.8 billion in 2018 and
is expected to expand at a CAGR of 14.2% over the forecast period.”
The global Biomarkers Market size is expected to reach over USD 118 billion by 2026, according to a new study
by Grand View Research Inc. It is projected to expand at a CAGR of 14.2% during the forecast period.
Technological advancements, high consumer awareness, and increasing funds for research and development
(R&D) activities are collectively propelling the market growth.
Drug discovery was estimated to be one of the highest revenue generating segments of the market.
Pharmaceutical companies are undertaking extensive R&D initiatives to develop targeted therapeutics.
Coordinated research efforts on biomarker development is a rising trend among commercial R&D organizations,
academic research institutions, federal government biomedical regulatory and research agencies, and
nonprofitable health foundations.
North America led the biomarker market in 2018, driven by high disease prevalence, proactive governmnet
initiatives, and substantial demand for personalized medicines. North America is anticipated to retain its
leading position throughout the forecast period. Asia Pacific is expected to witness the fastest regional growth,
spearheaded by India.
Some key players operating in the biomarkers market include F. Hoffmann-La Roche Ltd.; Abbott.; Epigenomics
AG; Agilent Technologies, Inc.; Johnson & Johnson Services, Inc; Siemens Healthcare Private Limited; Bio-Rad
Laboratories, Inc.; Thermo Fisher Scientific, Inc.; and Qiagen. Key players are developing novel kits and
therapies or drugs to target population in the areas with high unmet clinical needs.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/biomarkers-industry
Follow Us:
Further key findings from the study suggest:

Safety biomarkers held the largest market share of over 42% in 2018 due to reduction in drug attrition
and increasing awareness of routine healthcare checkups

Validation biomarkers is estimated to be one of the fastest growing segments

Personalized medicine is estimated to grow at a CAGR of 15.0% over the forecast period owing to
growing consumer awareness

Cancer held the largest market share in 2018, driven by an increase in global prevalence of cancer and
the presence of a strong pipeline of drugs

Cardiovascular diseases is projected to be the fastest growing segment throughout the forecast period,
supported by sedentary lifestyles and growing obese population.
Grand View Research has segmented the global biomarkers market on the basis of application, type, and
region:
Biomarkers Type Outlook (Revenue, USD Million, 2014 - 2026)

Safety

Efficacy

Validation
Biomarkers Application Outlook (Revenue, USD Million, 2014 - 2026)

Diagnostic

Drug Development

Personalized Medicine

Others
Biomarkers Disease Outlook (Revenue, USD Million, 2014 - 2026)

Cancer

Cardiovascular Diseases

Neurological Diseases

Immunological Diseases

Others
Follow Us:
Biomarkers Regional Outlook (Revenue, USD Million, 2014 - 2026)





North America
o
U.S.
o
Canada
Europe
o
U.K.
o
Germany
o
Spain
o
France
o
Italy
Asia Pacific
o
Japan
o
China
o
India
o
South Korea
o
Australia
Latin America
o
Brazil
o
Mexico
o
Argentina
MEA
Follow Us:
o
South Africa
o
Saudi Arabia
o
UAE
Table of Content of Biomarkers Market
Chapter 1 Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources & third party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biomarkers Market Variables, Trends & Scope
3.1. Biomarkers Market Lineage outlook
3.1.1. Clinical diagnostics market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Regulatory Framework
3.3.1. Reimbursement framework
3.3.2. Standards & compliances
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of chronic diseases
3.4.1.2. Technological advancements
3.4.1.3. Funding for biomrkers
3.4.2. Market restraint analysis
3.4.2.1. Reimbursement policies
Follow Us:
3.5. Biomarkers Market Analysis Tools
3.5.1. Industry analysis - Porter’s
3.5.1.1. Supplier power: (High due to large number of manufacturers)
3.5.1.2. Buyer power: (Moderate due tolong-term contracts with manufacturers)
3.5.1.3. Substitution threat: (Moderate due to no/less external substitutes)
3.5.1.4. Threat from new entrant: (Moderate due to limited number of new players)
3.5.1.5. Competitive rivalry: (High due to mergers & acquisitions by major players)
3.5.2. PESTEL analysis
3.5.2.1. Political landscape
3.5.2.2. Environmental landscape
3.5.2.3. Social landscape
3.5.2.4. Technology landscape
3.5.2.5. Legal landscape
3.5.3. major deals & strategic alliances analysis
3.5.3.1. Joint ventures
3.5.3.2. Mergers & acquisitions
3.5.3.3. Licensing & partnership
3.5.3.4. Technology collaborations
3.5.3.5. Strategic divestments
Chapter 4. Biomarkers Market - Competitive Analysis
4.1. Recent Developments & Impact Analysis, By Key Market Participants
4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
4.3. Vendor Landscape
4.3.1. List of key distributors and channel partners
4.3.2. Key company market share analysis, 2018
4.4. Public Companies
4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key
serviceable industries, key alliances)
4.4.2. Company Market Share
4.4.3. Competitive Dashboard Analysis
4.4.4. Market Differentiators
Follow Us:
4.4.5. Synergy Analysis: Major Deals & Strategic Alliances
4.5. Private Companies
4.5.1. List of key emerging companies
4.5.2. Regional network map
4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance,
industry experience)
Chapter 5. Biomarkers Market: Type Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Type Market Share Analysis, 2018 & 2026
5.3. Biomarkers Market, by Type, 2014 to 2026
5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
5.4.1. Safety
5.4.1.1 Safety market, 2014 - 2026 (USD Million)
5.4.2. Efficacy
5.4.2.1 Efficacy market, 2014 - 2026 (USD Million)
5.4.3. Validation
5.4.3.1 Validation market, 2014 - 2026 (USD Million)
Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Application Market Share Analysis, 2018 & 2026
6.3. Biomarkers Market, by Application, 2014 to 2026
6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
6.4.1. Diagnostics
6.4.1.1 Diagnostics market, 2014 - 2026 (USD Million)
6.4.2. Drug development
6.4.2.1 Drug development market, 2014 - 2026 (USD Million)
6.4.3. Personalized medicine
6.4.3.1 Personalized medicine market, 2014 - 2026 (USD Million)
Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis
7.1. Definitions & Scope
7.2. Disease Market Share Analysis, 2018 & 2027
Follow Us:
7.3. Biomarkers Market, by Disease, 2014 to 2027
7.4. Market Size & Forecasts and Trend Analyses, 2014 to 2027 for the following,
7.4.1. Cancer
7.4.1.1 Cancer market, 2014-2027 (USD Million)
7.4.2. Cardiovascular disease
7.4.2.1 Cardiovascular disease market, 2014-2027 (USD Million)
7.4.3. Neurological disease
7.4.3.1 Neurological disease market, 2014-2027 (USD Million)
7.4.4. Immunological disease
7.4.4.1 Immunological disease market, 2014-2027 (USD Million)
7.4.5. Others
7.4.5.1 Others market, 2014-2027 (USD Million)
7.5. Disease Market, by Type, 2014 - 2026:
7.5.1. Cancer
7.5.1.1 Safety
7.5.1.1.1 Cancer biomarkers market, by safety, 2014 - 2026 (USD Million)
7.5.1.2 Efficacy
7.5.1.2.1 Cancer biomarkers market, by efficacy, 2014 - 2026 (USD Million)
7.5.1.3 Validation
7.5.1.3.1 Cancer biomarkers market, by validation, 2014 - 2026 (USD Million)
7.5.2. Cardiovascular diseases
7.5.2.1 Safety
7.5.2.1.1 Cardiovascular biomarkers market, by safety, 2014 - 2026 (USD Million)
7.5.2.2 Efficacy
7.5.2.2.1 Cardiovascular biomarkers market, by efficacy, 2014 - 2026 (USD Million)
7.5.2.3 Validation
7.5.2.3.1 Cardiovascular biomarkers market, by validation, 2014 - 2026 (USD Million)
7.5.3. Neurological disease
7.5.3.1 Safety
7.5.3.1.1 Neurological biomarkers market, by safety, 2014 - 2026 (USD Million)
7.5.3.2 Efficacy
Follow Us:
7.5.3.2.1 Neurological biomarkers market, by efficacy, 2014 - 2026 (USD Million)
7.5.3.3 Validation
7.5.3.3.1 Neurological biomarkers market, by validation, 2014 - 2026 (USD Million)
7.5.4. Imunological disease
7.5.4.1 Safety
7.5.4.1.1 Imunological biomarkers market, by safety, 2014 - 2026 (USD Million)
7.5.4.2 Efficacy
7.5.4.2.1 Imunological biomarkers market, by efficacy, 2014 - 2026 (USD Million)
7.5.4.3 Validation
7.5.4.3.1 Imunological biomarkers market, by validation, 2014 - 2026 (USD Million)
7.5.5. Others
7.5.5.1 Safety
7.5.5.1.1 Other biomarkers market, by safety, 2014 - 2026 (USD Million)
7.5.5.2 Efficacy
7.5.5.2.1 Other biomarkers market, by efficacy, 2014 - 2026 (USD Million)
7.5.5.3 Validation
7.5.5.3.1 Other biomarkers market, by validation, 2014 - 2026 (USD Million)
Chapter 8 Biomarkers Market: Regional Estimates & Trend Analysis, by Type, Application, & Disease
8.1 Biomarkers Market: Regional Movement Analysis, 2018 & 2026
8.2 Biomarkers Market: Leading Players, 2018:
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
Follow Us:
8.4 North America
8.4.1 North America biomarkers market, 2014 - 2026 (USD Million)
8.4.2 U.S.
8.4.2.1 U.S. biomarkers market, 2014 - 2026 (USD Million)
8.4.3 Canada
8.4.3.1 Canada biomarkers market, 2014 - 2026 (USD Million)
8.5. Europe
8.5.1 Europe biomarkers market, 2014 - 2026 (USD Million)
8.5.2 UK
8.5.2.1 UK biomarkers market, 2014 - 2026 (USD Million)
8.5.3 Germany
8.5.3.1 Germany biomarkers market, 2014 - 2026 (USD Million)
8.5.4 Spain
8.5.4.1 Spain biomarkers market, 2014 - 2026 (USD Million)
8.5.5 France
8.5.5.1 France biomarkers market, 2014 - 2026 (USD Million)
8.5.6 Italy
8.5.6.1 Italy biomarkers market, 2014 - 2026 (USD Million)
8.6 Asia Pacific
8.6.1 Asia Pacific biomarkers market, 2014 - 2026 (USD Million)
8.6.2 Japan
8.6.2.1 Japan biomarkers market, 2014 - 2026 (USD Million)
8.6.3 India
8.6.3.1 India biomarkers market, 2014 - 2026 (USD Million)
8.6.4 South Korea
8.6.4.1 South Korea biomarkers market, 2014 - 2026 (USD Million)
8.6.5 China
8.6.5.1 China biomarkers market, 2014 - 2026 (USD Million)
8.6.6 Australia
8.6.6.1 Australia biomarkers market, 2014 - 2026 (USD Million)
8.7 Latin America
Follow Us:
8.7.1 Latin America biomarkers market, 2014 - 2026 (USD Million)
8.7.2 Brazil
8.7.2.1 Brazil biomarkers market, 2014 - 2026 (USD Million)
8.7.3 Mexico
8.7.3.1 Mexico biomarkers market, 2014 - 2026 (USD Million)
8.7.4 Argentina
8.7.4.1 Argentina biomarkers market, 2014 - 2026 (USD Million)
8.8 MEA
8.8.1 MEA biomarkers market, 2014 - 2026 (USD Million)
8.8.2 South Africa
8.8.2.1 South Africa biomarkers market, 2014 - 2026 (USD Million)
8.8.3 United Arab Emirates
8.8.3.1 United Arab Emirates biomarkers market, 2014 - 2026 (USD Million)
8.8.4 Saudi Arabia
8.8.4.1 Saudi Arabia biomarkers market, 2014 - 2026 (USD Million)
Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Heat Map Analysis of Private Companies
9.2.1 Company size
9.2.2 Distribution network
9.2.3 Product portfolio
9.2.4 Segment coverage
9.2.5 Geographic presence
9.2.6 Collaborations
9.2.7 Conclusion
9.3 F-Hoffman La Roche Ltd.
9.3.1 Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.4 Abbott
Follow Us:
9.4.1 Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.5 Epigenomics AG
9.5.1 Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.6 General Electric Company
9.6.1 Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.7 Johnson & Johnson
9.7.1 Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.8 Thermo Fisher Scientific, Inc.
9.8.1 Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.9 Bio-Rad Laboratories, Inc.
9.9.1 Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.10 Siemens Healthcare Private Limited
9.10.1 Company overview
Follow Us:
9.10.1 Financila performance
9.10.2 Product benchmarking
9.10.3 Strategic initiatives
9.11 Qiagen
9.11.1 Company Overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
Follow Us:
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Follow Us:

The global Biomarkers Market size is expected to reach over USD 118 billion by 2026, according to a new study by Grand View Research Inc